Albiglutide (trade name Eperzan) was approved in March 2014 for use by adults with type 2 diabetes mellitus where diet and exercise do not lower high blood sugar levels sufficiently. The Institute for Quality and Efficiency in Health Care (IQWiG) has reviewed a dossier to determine whether the active substance in these patient groups compared with the appropriate comparator therapy offers an additional benefit.

There is an indication for a little added value for albiglutide plus metformin hydrochloride compared to metformin hydrochloride plus sulfonylurea, since hypoglycaemia occur less frequently.

For more details, go to: https://www.iqwig.de/de/presse/pressemitteilungen/pressemitteilungen/albiglutid-bei-typ-2-diabetes-anhaltspunkt-fur-geringen-zusatznutzen.6517.html?&et_cid=4&et_lid=%25208 [German]